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 ABSTRACT 
 
 
Pharmaceutical waste is an emerging form of waste with significant impacts on the 
environment. This study reports the results of a state-wide phone survey on 
pharmaceutical purchasing, use and disposal behavior among Vermont residents (n = 
421). The objectives of this study were: 1) to compare the demographic nature of 
populations who purchase and use medicaton to those associated with leftover 
medication, and 2) to evaluate the impact of disposal behavior in Vermont and to 
recommend strategies to minimize pollution. The findings of this study showed that 
approximately 93% of survey participants reported purchasing of medication, 60% 
reported leftover medication and 25% reported disposing of medications down-the-drain 
or via municipal trash, both of which are known pathways leading to environmental 
pollution. Results indicate that pharmaceutical waste is common in Vermont and that 
disposal behavior may be contributing towards pollution. The conclusion of this study is 
that better management of pharmaceutical waste is needed to protect the environment and 
public health.  
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CHAPTER 1: INTRODUCTION 
Pharmaceuticals are an emerging form of pollution with significant impacts on 
the environment. Increasing levels of pollution in the environment pose significant risks 
to ecological health (EPA, 2017b). Pharmaceutical compounds in the environment can 
be extremely toxic at extremely low levels. Some fish species may be at risk for 
population collapse from exposure to pharmaceutical levels equivalent to one drop of a 
medication in a lake (Kidd, 2015). The level of risk varies substantially according to 
each compound, however some studies show ecological risks may occur with 
concentrations as low as 5ppt (Kidd, 2015). Previous research shows that the level of 
risk can be very close to the median levels detected in the environment (Kolpin et al., 
2002). The loss of fish populations is an example of one of a potentially infinite number 
of possible effects on ecosystems (Daughton & Ternes, 1999). The Environmental 
Protection Agency now considers pharmaceuticals “contaminants of emerging concern” 
(EPA, 2017a).  
Pharmaceuticals enter the environment primarily through wastewater. In 
national reconnaissance studies, pharmaceuticals have been detected in 100% of 
wastewater samples (Loos et al., 2013), which is then discharged into rivers, lakes and 
streams, where the compounds remain persistent and ubiquitous, with serious potential 
effects. According to national statistics, detectable levels are present in over 80% of 
groundwater (Barnes et al., 2008), 80% of surface-water (Kolpin et al., 2002), and up to 
100% of drinking water sampled in highly urbanized areas in the United States 
(Furlong et al., 2017). Drinking water technology, like wastewater technology, was 
never designed to remove chemicals (Caban et al., 2015; Ternes et al., 2002). 
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Increasing levels in drinking water and wastewater imposes a significant burden on 
water providers (American Chemical Society, 2008). The costs of updating water 
systems, primarily designed for water treatment, for purposes of water purification, is 
financially and technologically out of reach for most communities (Shannon et al., 
2008).  
Pharmaceutical pollution is expected to increase, due to increasing use of 
medication (Kantor et al., 2015). According to national statistics, 25% of children, 50% 
of adults, and 90% of older adults age 65+ use prescription medications each month in 
the U.S. (CDC, 2013). Pharmaceutical use contributes towards the relatively constant 
level of pollution seen in wastewater (Roberts et al., 2016). In 2014, a pilot study in 
Burlington, VT detected 51 pharmaceutical compounds in wastewater and identified the 
consumer population as the source (Vatovec et al., 2016). Several findings suggest that 
disposal of leftover medication may be a significant source of pollution in the 
environment (Bound & Voulvoulis, 2005; Law et al., 2015).  
Previous research on lifecycle assessements have found that different strategies 
for disposal are each associated with their own set of socio-ecological consequences, 
depending on the method (Cook, 2012). Disposal impacts the health of the 
environment, as well as the health of communities, through various forms of pollution.  
One of the proposed solutions: The National Prescription Takeback Initiative is 
intended to minimize the impact of disposal on the environment (DEA, 2017). 
Consumers are encouraged to “takeback” medication, rather than dispose down-the-
drain, which contributes towards pollution in wastewater, or dispose through the trash, 
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which contributes towards groundwater pollution surrounding landfills (Daughton, 
2003).  
Greater research is needed on pharmaceutical purchasing, use and disposal 
behavior, in order to develop intervention strategies to minimize pharmaceutical 
pollution, such as encouraging proper disposal through takeback programs. Greater 
research is needed on leftover medication specifically, in order to develop strategies to 
prevent waste, minimize disposal and therefore minimize pollution in the environment. 
This study will address this need by examining the results of a statewide survey on 
consumer purchasing, use and disposal behavior. The first objective of this study was to 
compare the demographic nature of populations who purchase and use medicaton, to 
those associated with leftover medication. The second objective was to evaluate the 
impact of disposal behavior in Vermont, and to recommend strategies to minimize 
pollution. 
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CHAPTER 2: LITERATURE REVIEW 
2.1 Pharmaceuticals in the Environment 
 
Pharmaceuticals are an emerging form of water pollution. Hundreds of studies 
have evaluated the occurrence, fate and effects of pharmaceuticals on many different 
kinds of aquatic and terrestrial species (Boxall et al., 2012). Pharmaceuticals have been 
shown to effect aquatic species including bacteria, plankton, insects, crustaceans, 
amphibians, fish, as well as terrestrial species such as worms, waterfowl and birds 
(EPA, 2017). Adverse effects include behavioral changes (Macikova et al., 2014), 
genetic, biochemical, or endocrine disruption (Hotchkiss et al., 2008), retardation of 
growth (Brausch et al., 2012), deformation, physical mutation (Brooks, 2014), 
bioaccumulation among tissues and organs (van der Oost et al., 2003), effects on 
reproduction, morphological intersex changes (Neimuth & Klaper, 2015), 
developmental abnormalities among offspring (Overturf et al., 2015), sterility and 
mortality (EPA, 2017a), and eventually, population collapse (Kidd, 2015).  
Some pharmaceuticals are extremely toxic to aquatic life at extremely “low” 
concentrations. One of the most prescribed antidepressants, Prozac (fluoxetine), 
produces severe toxicity as low as 100ppt (Brooks, 2014). The most common diabetes 
medication, Metformin can change the sex of fish, as low as 40ppt (Neimuth & Klaper, 
2015). Carbamazepine, an antiepileptic medication, produces morbidity and mortality, 
as low as 18ppt (Ferrari et al., 2004). Zoloft, a popular antidepressant, as low as 5ppt 
(Schultz et al., 2011). At this scale, pharmaceutical pollution is like one drop in lake. 
Pharmaceuticals are present in the environment in trace amounts, typically in the parts 
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per trillion range. At this scale, pharmaceuticals may pose significant risks to ecological 
health (Brooks, 2014; Fent et al., 2006; Khetan & Collins, 2007).  
Very little is known about the full spectrum of potential risks to ecological 
health. Pharmaceuticals are introduced into the environment through continuous 
discharge of wastewater, which leads to a relatively constant level of pollution in rivers, 
lakes and streams (Roberts et al., 2016). Continuous use by the consumer population 
leads to continuous discharge into wastewater, which creates a “pseudo-persistence” to 
the levels of pollution in rivers (Daughton, 2003). Therefore, the levels in the 
environment, although relatively “low” due to dilution, are nevertheless constant and 
continuous. Aquatic life is therefore exposed to pharmaceuticals constantly and 
continuously. The constant discharge into the environment, combined with the actual 
persistence of the compounds further complicates the scale of the effects (Stackelberg 
et al., 2004). If a compound has ecotoxic properties, or endocrine disrupting properties, 
or bioaccumulation potential, the risks may go on for signficant periods of time 
(Halling-Sorensen et al., 1998). Aquatic life is exposed to a potentially infinite number 
of possible pollutants in rivers, leading to a potentially infinite number of possible bio-
chemical reactions and interactions, which may catalyze significant, cascading effects 
throughout ecosystems (Daughton, 2003).  
The lifespan of persistent compounds can measure in years, decades, or 
centuries and degradation of pharmaceuticals does not necessarily lead to less risk 
(Yamamoto et al., 2009). Pharmaceutical compounds may “degrade” into different 
compounds, or transform into “metabolites,” however these derivate compounds can be 
equally toxic, and sometimes more toxic than the parent compound (Donner et al., 
 6 
2013). Very little can be known about the full spectrum of risks, primarily due to the 
inherent limitations to studying and predicting such effects, both from a methodological 
as well as an epistemological standpoint (Daughton & Ternes, 1999). Ecosystems are 
an open system, where multiple organisms can be exposed to multiple chemicals 
simultaneously, at multiple points in their lifetime, at different stages of life, leading to 
a multiplicity of effects across time and space. Effects from long term, continuous 
lifecycle and multigenerational exposure to multiple chemicals, from constant exposure 
to “low” concentrations in water may produce “subtle” effects that are not easily 
detectable or measurable (Daughton & Ternes, 1999).  
2.2 Pharmaceuticals in Drinking Water 
 
As stated previously, pharmaceuticals enter the environment primarily through 
discharge of wastewater into the environment (Ashton et al., 2004; Nikolaou et al., 
2007; Roberts et al., 2016). Many municipalities rely on the same water body as a point 
of discharge for wastewater, but they also rely on the water body as the source of the 
community’s drinking water. 
Therefore, pollution in wastewater contributes towards pollution in rivers, 
which may increase potential pollution entering the drinking water cycle (Conley et al., 
2017). Pharmaceuticals are introduced into the wastewater cycle through consumer use 
of medication, which results in excretion down-the-drain, as well as direct disposal 
down-the-drain (Daughton, 2003a, 2003b). Conventional water technology does not 
fully remove pharmaceuticals (Luo et al., 2014; Y. Yang et al., 2017). Hundreds of 
studies document pharmaceuticals in wastewater. For example, a survey of 
contaminants in wastewater at 90 wastewater facilities across 16 countries in the EU 
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found pharmaceutical compounds in 100% of samples (Loos et al., 2013). Wastewater 
(along with pharmaceuticals, and other contaminants) is then discharged into surface 
waters or groundwater, where the pharmaceutical become a form of water pollution. 
Similarly, drinking water treatment does not fully remove pharmaceuticals (Caban et 
al., 2015; Ternes et al., 2002).  
Pharmaceutical contamination of drinking water has been documented in some 
of the largest cities in the world (American Chemical Society, 2008). In the US, recent 
reconnaissance surveys have found pharmaceuticals may be present in up to 50% of 
drinking water on a national scale (Focazio et al., 2008) and potentially up to 100% in 
highly urbanized areas (Furlong et al., 2017). Pharmaceuticals in drinking water has 
catalyzed growing concern about the potential risks to public health. Human health risk 
assessments often produce conflicting results (Williams & Brooks, 2012). The World 
Health Organization has concluded the potential risks to human health are inconclusive, 
primarily due to the lack of occurrence data, therefore, without data on the levels in 
drinking water, comprehensive risk assessments were not possible (WHO, 2011). 
Nevertheless, the WHO concluded that the evidence supports precaution and 
recommended measures to minimize pharmaceutical pollution in the environment. One 
proposed measure was to minimize consumer disposal of medication.  
2.3 Consumer Disposal as a Source of Environmental Pollution 
 
Pharmaceutical excretion and disposal are the two primary source-pathways by 
which the consumer population transfers pharmaceuticals into the environment 
(Daughton & Ruhoy, 2007). Currently, it is unknown whether pharmaceutical pollution 
of water is caused primarily by consumer excretion or by consumer disposal 
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(Glassmeyer et al., 2009; Ruhoy & Daughton, 2008). Each of these sources needs 
greater research, however some studies are emerging to give us a sense of the relative 
contribution of each source (Ruhoy & Daughton, 2007; Vatovec et al., 2016). 
Consumer disposal takes two forms. Disposal of leftover medication down-the-
drain directly contaminates the wastewater cycle (Bound & Voulvoulis, 2005), while 
disposal through municipal trash transfers pharmaceuticals to landfills, where 
compounds are known to leach into surrounding groundwater (Eggen et al., 2010). 
Previous research on disposal behavior has often been framed within greater efforts to 
encourage proper disposal through a governmental program called The National 
Prescription Drug Takeback initiative (DEA, 2017). Takeback programs are the 
official, recommended method of disposal. Since the program began in 2010, over 9 
million pounds of pharmaceutical waste has been turned into the program (DEA, 2017). 
However, this may represent only a fraction all pharmaceutical waste.  
Surveys find that leftover medication is commonly reported among surveyed 
populations. For example, in southern California 66% of respondents report leftover 
medication (Law et al., 2015), with up to 45% of survey respondents reporting disposal 
(Kotchen, Kallaos, Wheeler, Wong, & Zahller, 2009). Reviews on disposal behavior 
find a minority of consumers dispose of medication through takeback programs and the 
majority of consumers dispose of medication through the household, a known pathway 
leading to environmental pollution (Kusturica et al., 2017; Tong et al., 2011). This 
indicates that consumer disposal may be a significant source of environmental 
pollution. 
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2.4 Takeback Programs, a Strategy to Minimize Environmental Pollution 
 
Takeback programs were established to safely and securely collect medication 
from consumers, transfer the pharmaceutical waste to hazardous waste facilities, where 
the waste is disposed through incineration (EPA, 2017c). Although incineration may 
degrade chemicals, the potential of this method to reduce impacts on the environment 
remains unclear. Incineration, in general, is known to emit significant quantities of air 
pollution, which is known to adversely impact the health of surrounding communities 
(Rushton, 2003). Although the recommendation continues to be debated (Cook et al., 
2012; Daughton, 2012), takeback programs are increasingly regarded as an effective 
solution to address the need for proper disposal of pharmaceutical waste (Glassmeyer et 
al., 2009). 
2.5 Disposal Behavior and Participation in Takeback Programs 
 
Several studies have examined drug disposal behavior in the U.S. and 
internationally. Reviews of surveys on disposal behavior find that leftover medication 
generally has two fates: either it is kept or disposed (Kusturica et al., 2017; Tong et al., 
2011). A survey of 1,005 residents in southern California found most respondents 
dispose of medication through the trash (45%), flushing down the drain (28%), or 
takeback programs (10%) (Kotchen et al., 2009). Therefore, the primary method of 
disposal in the California study was through the trash and through flushing (73%). 
In Sweden, the primary method is to keep medication (55%) or to takeback 
medication (45%) (Persson et al., 2009). Significantly, this study found no participants 
had reported disposal down-the-drain or through the trash. A review of surveys on 
disposal behavior found that Sweden has the highest rate of participation in takeback 
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programs at 45% (Persson et al., 2009). Takeback programs have been more or less 
accessible in pharmacies for half a century in Sweden, which may account for distinctly 
different disposal behavior, compared to other countries such as the US, where 
takeback programs are beginning to be established. In Sweden, participation in 
takeback programs was 45%, as stated, however in the US, participation ranges from 
1% to 10% in communities with newly established programs (Kotchen et al., 2009; 
Vatovec et al., 2017), however participation may be up to 20% in more established 
programs (Zero Waste Washington, 2006; Ekedahl, 2006).  
The availability, accessibility, as well as the convenience of takeback programs 
are necessary conditions for participation, however other factors beyond the 
accessibility of the program itself, are likely more influential on disposal behavior, 
specifically participation in the program. Takeback programs are available in both 
communities in California and in Sweden, however household disposal is favored in the 
California study, and storage is favored in the Swedish study. Collectively, these 
findings suggest that the availability of a takeback program is not the only factor 
effecting consumer disposal behavior. 
Participation in takeback programs is strongly correlated with education, 
information, and consultation about proper disposal from a healthcare provider, as well 
environmental awareness of the potential impacts from improper disposal (Abahussain 
et al., 2006; Bashaar et al., 2017; Kotchen et al., 2009; Seehusen & Edwards, 2006). 
Therefore, this study sought to identify populations who may benefit from takeback 
programs and to develop strategies increase participation through education based 
policies.  
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CHAPTER 3: METHODS 
 
3.1 Survey Design, Participant Recruitment and Data Collection 
Data were collected through a phone survey administered at the University of 
Vermont between October and November of 2016. Trained interviewers recruited 
participants by calling a random sample of phone numbers with the Vermont area code 
802. Interviewers dialed each phone number at different points of the day on both 
weekdays and weekends, provided an overview of the survey content, read the 
confidentiality statement, asked for voluntary consent to participate in the survey and 
then proceeded to ask 27 questions while recording responses into an online survey 
database (Limesurvey, 2017). Questions included purchasing of medication, whether 
respondents ever have unused medication leftover, reasons why medication may be 
leftover, what they do with leftover medication, including methods of disposal and 
participation in takeback programs. Survey questions were designed to understand the 
demographic, geographic and behavioral nature of consumer pharmaceutical 
purchasing, use and disposal. This study was approved by the University of Vermont 
Institutional Review Board.  
3.2 Data Analysis 
Data were analyzed using SPSS social science statistical software (SPSS, 2017). 
Descriptive statistics were based on cross-tabulations to compare frequencies of 
different responses to questions, such as the percentage responding Yes or No to a 
question on pharmaceutical use. Pearson’s chi-square tests of significance were used to 
determine differences between groups associated with response variables that were 
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categorical in nature, independent samples t-tests, for differences between the ages of 
two response groups, and Anova tests, for the ages of three or more response groups.  
3.3 Framework for Assessing Environmental Impact of Disposal Behavior 
The Framework (Figure 1) defined and characterized disposal behavior into 
high, uncertain and low impact groups. Data on disposal were derived from a question: 
“in general, what do you do with leftover medication?” Multiple responses were 
possible, therefore some respondents reported multiple disposal methods with mixed 
impact. For example, one individual may report flushing (high impact) as well as taking 
back medication (low impact). Respondents with mixed behavior involving two or 
more disposal methods with different impact were categorized into the “higher” impact 
category. If a respondent reported at least one high impact method, they were grouped 
into high impact behavior. If a respondent only reported low impact methods, they were 
grouped into the low impact behavioral group. For the uncertain group, respondents 
reported at least one uncertain method, and reported no high impact methods, but may 
have reported additional, low impact behavior. This criteria was used to categorize the 
disposal behavior of the survey population into three mutually exclusive groups, which 
enabled statistical and comparative analyses.  
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CHAPTER 4: ARTICLE 
Abstract  
Pharmaceutical waste is an emerging form of waste with significant impacts on the 
environment. This study reports the results of a state-wide phone survey on 
pharmaceutical purchasing, use and disposal behavior among Vermont residents (n 
= 421). The purpose of this study was to identify populations associated with 
leftover medication, evaluate the environmental impact of disposal behavior, and to 
recommend strategies to minimize environmental pollution. Results indicate that 
leftover medication is common in Vermont (60% of the sample reported leftover 
medication), leftover medication is associated with higher income populations (43% 
of those with <$25,000 had leftover medication, compared to 78% of those with 
>$100,000, p=0.0002), and that disposal may be contributing towards 
environmental pollution (25% of the sample reported disposal behavior associated 
with high environmental impact). Participants whose physician or pharmacist 
recommended takeback programs for disposal were more likely to return leftover 
medications. The findings of this study suggest that public campaigns seeking to 
increase participation in takeback programs would likely be effective coming from 
a doctor or pharmacist. 
.
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4.1 Introduction & Literature Review 
Pharmaceuticals are an emerging form of waste with significant impacts on the 
environment. According to national statistics, 25% of children, 50% of adults, and 90% 
of older adults age 65+ use prescription medications each month in the U.S. (CDC, 2013). 
A significant amount of medication is prescribed to the consumer population each year, 
however a significant amount of medication may go unused. Between 40% and 66% of 
consumers report leftover medication (Banwat et al., 2016; Kreisberg & Zheng, 2011; 
Kusturica et al., 2016; Law et al., 2015; Vatovec et al., 2017). The fate of medication that 
may become “leftover” due to partial or non-use is largely unstudied. Excess medication 
may become a risk factor for abuse (Birnbaum et al., 2011), childhood poisoning (Warner 
et al., 2011), adult overdose (Bohnert et al., 2011), or illicit diversion (Dart et al., 2015). 
In particular, excess prescription of opioids is gaining increasing attention (Bicket et al., 
2017). Leftover medication is an emerging form of waste, with several unintended 
consequences. Generally, literature shows that leftover medication has two fates: either 
it is kept or disposed of (Tong et al., 2011). If medication is kept in the household, excess 
medication may impact public health in a variety of ways, otherwise if medication is 
disposed, the medication may enter the environment and contribute towards the 
increasing levels of pharmaceutical pollution detected in the environment. Greater 
research is needed on leftover medication and disposal, in order to develop intervention 
strategies to minimize the potential public health impacts of leftover medication, and to 
minimize the potential environmental impacts of pharmaceutical disposal. 
Pharmaceuticals are found in virtually all wastewater (Loos et al., 2013), 
between 50% to 80% of groundwater (Barnes et al., 2008), over 80% of surface-water 
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in the U.S., (Kolpin et al., 2002), and up to 100% of drinking water in highly urbanized 
areas (Furlong et al., 2017). Pharmaceuticals in the environment pose significant risks 
to ecological health (EPA, 2017b) and may pose risks to public health (WHO, 2011). 
The Environmental Protection Agency now considers pharmaceuticals “contaminants 
of emerging concern” (EPA, 2017a).  
In 2014, a pilot study in Burlington, VT detected 51 pharmaceutical compounds 
in wastewater and identified the consumer population as the source (Vatovec et al., 
2016). Disposal of leftover medication is a known source of pharmaceuticals in 
wastewater (Daughton, 2003). In November 2016, researchers conducted a statewide 
survey of Vermont residents to collect data on pharmaceutical purchasing, use and 
disposal behavior, to assess the consumer population as a source of pollution. The 
purpose of this study was to identify populations associated with leftover medication, 
evaluate the environmental impact of disposal behavior, and to recommend strategies to 
minimize environmental pollution. The findings of this study are intended to provide a 
greater understanding of disposal behavior, in order to assist efforts to minimize 
pollution in the environment.  
Currently, the preferred method for minimizing pharmaceutical pollution from 
leftover medication is to encourage participation in drug takeback programs. The 
National Prescription Takeback Initiative is the official, recommended form of disposal 
of pharmaceutical waste (DEA, 2017). Public education campaigns have been initiated 
to encourage disposal through takeback programs (Product Stewardship Council, 2017).  
This study assessed the disposal behavior of populations with leftover 
medication in Vermont, in order to evaluate whether behavior may differ systematically 
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in terms of demographic characteristics.  If this is the case, a campaign to increase 
participation in takeback programs may require different strategies, in order to increase 
participation across the whole target population. Therefore, understanding purchasing, 
use and disposal behavior is needed, in order to better understand how to utilize 
takeback programs as a strategy to reduce pharmaceutical pollution in the environment.  
4.2 Methods 
4.2.1 Survey Design, Participant Recruitment and Data Collection 
Data were collected through a phone survey administered at the University of 
Vermont between October and November of 2016. Trained interviewers recruited 
participants by calling a random sample of phone numbers with the Vermont area code 
802. Interviewers dialed each phone number at different points of the day on both 
weekdays and weekends, provided an overview of the survey content, read the 
confidentiality statement, asked for voluntary consent to participate in the survey and 
then proceeded to ask 27 questions while recording responses into an online survey 
database (Limesurvey, 2017). Questions included purchasing of medication, whether 
respondents ever have unused medication leftover, reasons why medication may be 
leftover, and what they do with leftover medication, including methods of disposal and 
participation in takeback programs. Survey questions were designed to understand the 
demographic, geographic and behavioral nature of consumer pharmaceutical 
purchasing, use and disposal. This study was approved by the University of Vermont 
Institutional Review Board.  
4.2.2 Data Analysis 
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Data were analyzed using SPSS social science statistical software (SPSS, 2017). 
Descriptive statistics were based on cross-tabulations to compare frequencies of 
different responses to questions, such as the percentage responding Yes or No to a 
question on pharmaceutical use. Pearson’s chi-square tests of significance were used to 
determine differences between groups associated with response variables that were 
categorical in nature, independent samples t-tests, for differences between the ages of 
two response groups, and Anova tests, for the ages of three or more response groups.  
4.2.3 Framework for Assessing Environmental Impact of Disposal Behavior 
The Framework (Figure 1) defined and characterized disposal behavior into 
high, uncertain and low impact groups. Participants were assigned to high, uncertain, or 
low impact behavioral categories, based on their reported method: dispose, keep, or 
return. Flushing and trash methods were defined as high impact behavior because 
flushing and trash methods introduce pharmaceuticals directly into the environment 
(Daughton, 2003), where the compounds are known to remain persistent (Yamamoto et 
al., 2009). Keeping medication was classified as having uncertain impact because the 
impact on the environment is uncertain. Finally, returning medication to takeback 
programs was defined as low impact because takeback programs are recommended for 
low environmental impact (EPA, 2017c). 
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Figure 1. Framework for Assessing Impact of Disposal Behavior 
 
Data on disposal were derived from a question: “In general, what do you do 
with leftover medication?” Multiple responses were possible, therefore some 
respondents reported multiple disposal methods with mixed impact. For example, one 
individual may report flushing (high impact) as well as taking back medication (low 
impact). Respondents with mixed behavior involving two or more disposal methods 
with different impact were categorized into the “higher” impact category. This criterion 
was used to categorize the disposal behavior of the survey population into three 
mutually exclusive groups.  
4.3 Results 
4.3.1 Demographics of the Survey Sample Population 
The survey sample included a total of 421 participants. This sample size 
provides a 95% confidence interval of +/- 5%, for estimated proportions. Overall, 
demographics of the survey population were representative of the Vermont population 
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in terms of gender, income, and locality, however the sample is slightly skewed 
towards older populations with more formal education (Table 1). The sample included 
slightly more females (54%) than males (46%) and the vast majority of respondents 
identified as white (98%). The sample was equally distributed above and below the 
state’s median household income ($55,000); with 37% below and 41% above median 
income. The age of the sample population was moderately skewed towards older 
populations with 60% of the sample being 51 or older, compared to 40% of the 
Vermont general population, of the same age. The educational distribution of the 
sample was also moderately skewed towards higher formal education with 54% of the 
sample reporting a college education or higher, compared with 36% of the Vermont 
population. In terms of geographic locality: rural, urban and suburban, the sample 
population was similar to the Vermont population.   
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Table 1. Demographics of Sample vs. Vermont Population. 
Demographics 
Survey 
Sample 
n (%) 
Vermont  
Population1   
(%) 
Gender N = 419  
Female 221 (54%) (54%) 
Male 192 (46%) (46%) 
Income  N = 360  
<$25,000 58 (16%) 
(37%) 
 
 $25 to $50,000 75 (21%) 
$50 to $75,000 81 (23%) $55,000 (median) 
$75 to $100,000 67 (19%) 
(41%)  
>$100,000 79 (22%) 
Age N = 401  
18 to 30  52 (13%) (13%) 
31 to 40 40 (10%) (11%) 
41 to 50 69 (17%) (13%) 
51 to 60 84 (21%) (16%) 
61 to 70 79 (20%) (13%) 
71 to 80 60 (15%) (7%) 
81 to 90 22 (6%) (4%) 
Education  N = 402  
<High School 11 (3%) (8%) 
High School 67 (17%) 
(44%) (56%) Some College 71 (18%) 
Associates 38 (10%) 
Bachelor 108 (27%) 
(53%)  (36%) 
Post graduate 107 (27%) 
Locality  N = 394  
Rural 243 (61%) (58%) 
Urban 60 (15%) (14%) 
Suburban 91 (23%) (22%) 
Health Insurance N = 356  
Uninsured 6 (2%) (4%) 
Medicare/aid 134 (38%) (39%) 
Private  216 (61%) (55%) 
Note. Percentages rounded to nearest whole number.  
1Vermont population statistics obtained through state census (Census, 
2017). 
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4.3.2 Populations associated with Purchasing, Use & Leftover Medication 
The vast majority of the survey population reported purchasing medication 
(93%), the majority reported leftover medication (60%), and of those with leftover 
medication, approximately half kept the medication (48%), while the other half 
reported disposal (52%) (Table 2). 
Table 2. Survey Population reporting 
Purchasing, Use & Leftover Medication. 
Purchasing of Medication 
N = 421 
n = 392 
 (93%) 
Leftover Medication  
n = 254 
(60%) 
Fate of Medication 
What do you do with leftover medication?  
Disposal 
n = 133 
(52% of leftover population) 
(32% of total population) 
Keep 
n = 121  
(48%) 
(29%) 
Disposal 
Methods* 
n (%) 
 
 
Fate  
Unknown 
 
Takeback  
Trash 
Flush 
96 (72%) 
81 (61%) 
32 (25%) 
Environmental Impacts  
Public 
Health 
Impacts  
Note. Total Sample Population: N = 421.  
*Multiple responses possible.  
 
4.3.3 Populations associated with Disposal Behavior 
The findings of this study indicates that disposal behavior varies according to the 
method of disposal. Of those who reported disposal of medication (n = 113), 72% 
reported participating in takeback programs, 61% reported trash disposal, and 25% 
reported flushing down-the-drain (Table 2). Participation in takeback programs was 
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often reported alongside other behaviors. The majority of those who reported 
participation also reported multiple, additional methods, often with higher impact, and 
therefore were categorized into higher impact behavior, based on the criteria outlined in 
the Framework (Figure 1). For example, 72% reported participation (Table 2), but only 
26% reported participation as their only disposal method and therefore only 26% were 
categorized as having exclusively low impact behavior (Table 3). 
4.3.4 Evaluating Environmental Impact of Disposal Behavior 
According to the results of this study, 60% of the sample population reported 
leftover medication (Table 2), and of those with leftover medication, disposal behavior 
was distributed among high (42%), uncertain (32%), and low impact behavior (26%) 
(Table 3).  
Table 3. Disposal Behavior in the Survey Population 
based on High, Uncertain and Low Impact Behavioral Groups. 
Disposal 
Method 
Behavioral 
Groups  
based on 
Environmental 
Impact 
 
n 
% of  
Sample with 
Leftover 
Medication 
(n = 254) 
% of  
Total 
Sample  
(n = 421) 
 
 Flush, Trash High 107 42% 25% 
 Storage Uncertain 80 32% 19% 
 Takeback Low 67 26% 16% 
 
Respondents who disposed of medication either disposed through the trash or 
through flushing (42%), or exclusively through takeback programs (26%) (Table 3). 
Therefore, disposal behavior produced mixed results, which suggests that participation 
in takeback programs can be improved. The total percentage of respondents who reported 
trash and flushing was 25% (Table 3), keeping was 29% (Table 2), and takeback was 
23% (96 of 421) (Table 2). 
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4.3.5 Demographics of Populations associated with Leftover Medication  
 
Populations associated with leftover medication differ significantly based on 
income and health insurance. Income (p = 0.002) and health insurance (p = 0.053) were 
the only demographics statistically related to leftover medication (Table 5). Participants 
with higher income and those with private insurance reported significantly higher 
prevalence of leftover medication, compared to lower income groups, with public 
insurance through Medicare/aid. No significant differences were found between 
populations who disposed of medication or kept medication, except for gender (p = 
0.012) (Table 5). Women were more likely than men to report disposal of medication, 
and men were more likely than women to report keeping medication, and therefore 
keeping vs. disposal differed based on gender, however there were no significant 
demographic differences when disposal behavior was grouped into high, uncertain and 
low impact groups. All demographic populations were distributed approximately 
equally across high, uncertain, and low impact behavioral groups. Overall, disposal vs. 
keeping behavior differed based on gender, however disposal behavior (high, uncertain, 
low environmental impact) did not show any significant differences in terms of 
demographics. 
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Table 4. Demographics of Populations 
associated with Leftover Medication. 
 
Medication 
N = 412 
Demographics 
Leftover 
n = 254  
(60%) 
None  
Leftover 
n = 158 
(39%) 
Gender  p = 0.188 
Female  141 (64%) 78 (36%) 
Male 109 (59%) 77 (41%) 
Income  *p = 0.002 
<$25,000 25 (43%) 33 (57%) 
$25 to $50,000 41 (55%) 34 (45%) 
$50 to $75,000 45 (70%) 25 (30%) 
$75 to $100,000 55 (72%) 22 (28%) 
>$100,000 58 (78%) 21 (22%) 
Age p = 0.494 
Mean 54 54 
18 – 30  28 (54%) 24 (46%) 
31 – 40  29 (74%) 10 (26%) 
41 – 50  46 (68%) 22 (32%) 
51 – 60  53 (63%) 31 (37%) 
61 – 70  47 (60%) 31 (40%) 
71 – 80  35 (58%) 25 (42%) 
> 80 10 (63%) 6 (37%) 
Education  p = 0.252 
≤ High School 46 (59%) 32 (41%) 
Some College 64 (60%) 43 (40%) 
Bachelor 63 (59%) 45 (41%) 
Post graduate 75 (70%) 32 (30%) 
Locality  p = 0.154 
Rural 159 (66%) 82 (34%) 
Suburban 54 (59%) 37 (41%) 
Urban 32 (53%) 28 (47%) 
Health Insurance *p = 0.053 
Medicare/aid  76 (57%) 58 (43%) 
Private 144 (67%) 71 (33%) 
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Table 5. Demographics of Populations associated with  
Disposal & Environmental Impact. 
 
Fate of Leftover 
Medication 
N = 254 
Environmental Impact of  
Disposal Behavior 
N = 254 
Demographics 
Disposal 
n = 133  
(52%) 
Keep 
n = 121  
(48%) 
Low 
n = 67 
(26%) 
Uncertain 
n = 80 
(32%) 
High 
n = 107 
(42%) 
Gender  *p = 0.012 p = 0.077 
Female  75 (75%) 25 (25%) 43 (31%) 38 (27%) 60 (42%) 
Male 41 (56%) 32 (44%) 22 (20%) 42 (39%) 45 (41%) 
Income  p = 0.417 p = 0.674 
<$25,000 9 (56%) 7 (44%) 9 (37%) 8 (33%) 8 (29%) 
$25 to $50,000 15 (60%) 10 (40%) 12 (29%) 14 (34%) 15 (36%) 
$50 to $75,000 28 (74%) 10 (26%) 12 (22%) 14 (25%) 29 (53%) 
$75 to $100,000 27 (77%) 8 (23%) 12 (27%) 14 (32%) 18 (41%) 
>$100,000 27 (64%) 15 (36%) 15 (26%) 21 (36%) 22 (38%) 
Age p = 0.414 p = 0.091 
Mean 51 54 56 51 55 
18 – 30  14 (64%) 8 (36%) 2 (7%) 12 (44%) 13 (49%) 
31 – 40  18 (78%) 5 (22%) 9 (31%) 8 (28%) 12 (41%) 
41 – 50  19 (65%) 10 (35%) 10 (22%) 11 (41%) 25 (54%) 
51 – 60  28 (65%) 15 (35%) 13 (25%) 22 (25%) 18 (34%) 
61 – 70  20 (69%) 9 (31%)s 14 (29%) 12 (35%) 21 (45%) 
71 – 80  12 (57%) 9 (43%) 13 (28%) 12 (30%) 9 (26%) 
> 80 2 (66%) 1 (33%) 5 (50%) 3 (30%) 2 (20%) 
Education  p = 0.542 p = 0.227 
≤ High School 18 (72%) 7 (28%) 14 (30%) 11 (24%) 21 (45%) 
Some College 29 (66%) 15 (34%) 18 (29%) 21 (33%) 24 (38%) 
Bachelor 25 (58%) 18 (42%) 9 (15%) 26 (42%) 27 (44%) 
Post graduate 41 (70%) 17 (29%) 24 (32%) 22 (29%) 29 (39%) 
Locality  p = 0.687 p = 0.681 
Rural 72 (66%) 37 (34%) 42 (26%) 48 (30%) 68 (43%) 
Suburban 27 (73%) 10 (27%) 11 (20%) 21 (39%) 22 (41%) 
Urban 14 (64%) 8 (36%) 10 (32%) 9 (29%) 12 (39%) 
Health Insurance p = 0.659 p = 0.409 
Medicare/aid  36 (69%) 16 (31%) 21 (28%) 23 (31%) 30 (40%) 
Private 69 (66%) 36 (34%) 30 (21%) 49 (34%) 65 (45%) 
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4.3.6 Disposal Behavior correlates with Education on Disposal, not 
Demographics  
 
Although disposal behavior (high, uncertain and low impact) may not differ 
significantly among different demographic populations, the disposal behavior of 
participants in this study differed significantly based on whether a participant had been 
exposed to education, awareness and information about disposal (Table 6). Those who 
had lower impact behavior, namely those who had participated in takeback programs, 
were more likely be aware of environmental pollution, and to have received information 
on disposal from a doctor or pharmacist. Thus, awareness of environmental pollution, 
and information and education from a healthcare provider were both highly related to 
lower impact disposal behavior. Notably, awareness about takeback programs in and of 
itself, was not correlated with participation in takeback programs.  
Table 6. Education, Awareness & Disposal Behavior. 
 Environmental Impact of  
Disposal Behavior 
Low Uncertain High 
Takeback 
Programs 
Keep, 
Storage 
Trash, 
Flush 
Awareness of Takeback 
Programs, N = 157  
p = 0.280 
Yes   77 (49%)    6 (5%)  47 (41%) 63 (54%) 
No   80 (51%)   1 (2%) 12 (30%) 28 (68%) 
Awareness of Pollution in 
Environment, N = 249  
*p = 0.003 
Yes   152 (61%) 72 (36%)  65 (33%) 61 (31%) 
No    97 (39%) 6 (12%) 14 (27%) 31 (61%) 
Information on Disposal  
Received, N = 252 
*p = <0.001 
Yes   204 (81%) 74 (36%) 66 (32%) 66 (32%)  
No    48 (19%) 1 (2%) 14 (30%) 31 (67%) 
from a Physician, N = 244 *p = 0.014 
Yes   34 (14%) 15 (46%)   7 (22%) 11 (33%) 
No    210 (86%) 52 (24%) 73 (33%) 94 (43%) 
from a Pharmacist, N = 247 *p = 0.030 
Yes   49 (20%) 23 (46%) 11 (22%) 16 (32%) 
No   197 (80%) 44 (22%) 66 (33%) 87 (44%) 
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4.4 Discussion 
 
Baseline results indicate that purchasing, use and leftover medication were 
commonly reported by the survey population. The vast majority of respondents had 
purchased medication within the last year (93%), which is consistent with national 
statistics (CDC, 2013). The majority of respondents reported partial or incomplete use of 
medication, as evidenced by 60% of the sample reporting leftover medication. This 
finding is consistent with other studies, which also find that leftover medication is 
common among surveyed populations. As stated previously, between 40% and 66% of 
populations report leftover medication (for example, Law et al., 2015).  
Generally, the disposal behavior of the survey population appears to be similar to 
other surveyed populations (Tong et al., 2011). A significant finding of this study was 
that the total percentage of the survey population associated with high impact disposal 
behavior was 25%, thereby indicating that a potentially significant percentage of 
pharmaceutical waste in Vermont may be entering the environment through consumer 
disposal, either through landfills (via trash disposal) or through wastewater (via flushing). 
Participation in takeback programs in Vermont was 72% among those who 
reported disposal of medication. Generally, the participation rate in Vermont appears to 
be substantially higher than other survey populations (Zero Waste Washington, 2006; 
Ekedahl, 2006; Persson, 2009; Braund et al., 2009). A significant finding of this study 
indicates that participation in takeback programs is often reported alongside other 
disposal behaviors associated with environmental pollution. Among those who 
disposed of medication, 72% reported participation, however only 26% reported 
participation as their only disposal method, which is equivalent to 16% of the total 
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sample. Therefore, 16% of the total sample population reported participation as their 
only method of disposal. As stated previously, an additional 25% of the sample 
reported high impact disposal methods, namely down-the-drain or through the trash. 
The mixed nature of disposal behavior suggests that greater efforts are needed to 
encourage proper disposal through takeback programs. 
Education and outreach-based campaigns could increase participation. 
Education and information, specifically on disposal has been shown to be an important 
variable influencing consumer disposal behavior (Abahussain et al., 2006; Bashaar et 
al., 2017; Kotchen et al., 2009; Seehusen & Edwards, 2006). Based on the results of 
this study, results support education as a potential intervention to increase participation 
in takeback programs. Those who had participated in takeback programs were highly 
associated with being aware of environmental pollution, and having previously received 
information on disposal from a doctor or pharmacist, however awareness of takeback 
programs in and of itself, showed no significant influence on disposal behavior.  
The target population for takeback programs would be those with leftover 
medication, and more specifically, populations with high impact disposal behavior. The 
demographic characteristics of those with high impact disposal behavior were not 
significantly different from those with other disposal behavior. The only difference 
between participants associated with high impact behavior vs. low impact behavior was 
education on disposal. Those with high impact behavior were significantly less likely to 
be aware of the potential environmental impact of disposal, and significantly less likely 
to have received information on disposal.  
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Although there may have not been any patterns in terms of disposal behavior, 
the sample population reporting leftover medication had significantly higher income 
and was more likely to have private insurance. This suggests that pharmaceutical waste 
is likely a socio-economic issue. Initially, pharmaceutical waste was expected to be an 
issue related to age. Higher rates of leftover medication were expected among older 
populations, given the fact that older populations are prescribed more medication 
(CDC, 2013). The findings of this study suggest that waste is likely related to income, 
rather than age, and that disposal behavior is likely related to education on disposal, 
rather than demographics. Therefore, the results of this study support two potential 
strategies to increase participation in takeback programs: 1) incorporating socio-
economic based strategies into public outreach and educational campaigns in clinics 
and pharmacies and 2) encouraging clinicians and pharmacists to educate and 
disseminate information on disposal to patients and consumers of medication. 
4.5 Conclusion 
The findings of this study indicate that pharmaceutical waste may be a 
significant form of waste, and that consumer disposal behavior may be contributing 
towards environmental pollution. Public campaigns seeking to increase participation in 
takeback programs would likely be effective coming from a doctor or pharmacist who 
communicates awareness of the program itself, alongside awareness of the impact of 
improper disposal, specifically the environmental pollution associated improper 
disposal. Public campaigns directed towards higher income populations may be a useful 
strategy to increase participation in takeback programs. Greater research is needed on 
populations associated with leftover medication and consumer disposal behavior, in 
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order to develop more comprehensive strategies to increase participation in takeback 
programs.  
The limitation of this study is that it is based on data from one state, therefore 
results may not be easily generalizable. When variables were stratified, sample size 
became small in some categories, which reduces statistical power. This study did not 
measure the proportion or quantity of medication leftover, so the scale of 
pharmaceutical waste is unknown, nor did the study measure the levels of pollution 
resulting from disposal, so the actual impact of consumer disposal as a source of 
pollution is not known. The strength of this study is that it gives a first look at the 
prevalence of leftover medication and the potential environmental impact of consumer 
disposal behavior on a statewide basis.  
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CHAPTER 5: ADDITIONAL RESULTS 
5.1 Populations associated with  
Purchasing vs. Leftover Medication 
 
The vast majority of the survey population had purchased medication (n = 392, 
93%), while the majority had reported leftover medication (n = 254, 60%) (Table 7). 
 
Table 7. Purchasing, Use & Leftover Medication.  
Purchasing of Medication 
N = 421 
n = 392 
 (93%) 
Partial Use Full Use 
Some 
Leftover 
n = 254 
(60% of the Purchasing population) 
None 
Leftover 
n = 138 
(40%) 
 
Several statistically significant demographic differences within the survey population 
were found regarding those who reported purchasing medication and those who 
reported having leftover medication. Purchasing of prescription medication was 
statistically associated with all demographics: age, income, education, locality and 
insurance, excluding gender. Significantly higher purchasing was reported by older 
populations, with lower income, lower education, suburban/urban status, and public 
insurance through Medicare/aid. Lower purchasing was reported by younger 
populations, and higher income populations, with higher education, rural status, and 
private insurance.  
Leftover medication was statistically associated with income and health 
insurance (Table 8). Higher income populations with private insurance reported 
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significantly more leftover medication, compared to lower populations who reported 
significantly less.  
Income and health insurance were the only two demographics statistically 
associated with both purchasing and leftover. Income was negatively related to 
purchasing of prescription medication (p = 0.009) but positively related to leftover 
medication (p = 0.002) (Table 8). Insurance was also significantly related to purchasing 
of prescription medication (p = 0.003) and leftover medication (p = 0.053). Lower 
income groups with public insurance reported higher purchasing, but lower income 
groups with public insurance reported the least leftover. Higher income groups with 
private insurance reported lower purchasing, but more leftover. Age was also clearly 
related to purchasing and use of medication (p = 0.009), however the relationship 
between age and leftover medication was not statistically related (Table 8). 
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Table 8. Statistical Associations in the Demographics of  
Purchasing vs. Leftover Populations 
 OTC 
Purchasing 
Prescription 
Purchasing 
Leftover 
Medication 
Demographics 
Average 
Quantity  
N = 421 
Average 
Quantity  
N = 421 
% of 
Population  
N = 254  
(60%) 
Gender  p = 0.345 p = 0.531 p = 0.188 
Female  2.6 2.9 141 (64%) 
Male 2.5 2.8 109 (59%) 
Income  p = 0.236 *p = 0.009 *p = 0.002 
<$25,000 2.9 4.3 25 (43%) 
$25 to $50,000 2.4 3.8 41 (55%) 
$50 to $75,000 2.7 3.1 45 (70%) 
$75 to $100,000 2.4 2.5 55 (72%) 
>$100,000 2.7 2.0 58 (78%) 
Age p = 0.525 *p = 0.021 p = 0.494 
18 – 30  2.5 1.8 28 (54%) 
31 – 40  3.5 1.9 29 (74%) 
41 – 50  2.8 2.7 46 (68%) 
51 – 60  2.2 2.4 53 (63%) 
61 – 70  2.2 3.6 47 (60%) 
71 – 80  2.8 4.2 35 (58%) 
> 80 2.5 4.9 10 (63%) 
Education  p = 0.421 *p = 0.057 p = 0.252 
≤ High School 3.0 3.5 46 (59%) 
Some College 2.4 3.2 64 (60%) 
Bachelor 2.6 2.5 63 (59%) 
Post graduate 2.6 2.6 75 (70%) 
Locality  p = 0.095 *p = 0.058 p = 0.154 
Rural 2.3 2.5 159 (66%) 
Suburban 2.9 3.8 54 (59%) 
Urban 2.6 3.4 32 (53%) 
Insurance p = 0.398 *p = 0.003 *p = 0.053 
Medicare/aid  3.0 4.3 76 (57%) 
Private 2.5 2.0 144 (67%) 
Note. Total sample population: N = 421.   
* Designates statistical significance at α = 0.05.  
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CHAPTER 6: DISCUSSION 
 
6.1 Pharmaceutical Waste May be Significant 
 
Prevalence: How common is leftover medication? The most important finding 
from this study is that 60% of the population in Vermont reported leftover medication. 
As stated previously, this finding is consistent with other studies, which find leftover 
medication is common among surveyed populations. An additional question is whether 
specific demographic populations are commonly associated with leftover medication.  
Volume and Scale of Waste: How much is leftover?  
Several studies have measured the amount, quantity and weight of pharmaceutical 
waste (Stewart et al., 2015), while other studies have calculated the proportion of waste, 
based on the amount disposed and the amount of medication returned unused to takeback 
programs (Yang et al., 2015). These studies provide ratios between use and non-use, a 
metric of proportion, which are often combined with quantity and weight measurements, 
to give us a sense of the scale, volume or magnitude of pharmaceuticals as a form of 
waste. For example, in the state of Maine, researchers estimated that 24% of dispensed 
medication had been used, and that 76% of medication had been wasted, based on 
calculations of how much was dispensed on the prescription bottle, and how much was 
returned unused to takeback programs (Stewart et al., 2015). A similar study from a one-
day event in Lansing, Michigan estimated 34% of medication had been used, based on 
66% of medication being returned unused (Yang et al., 2015). A more comprehensive 
study, across six states over five years, found less than 50% of medication had been used, 
and thus, greater than 50% had been wasted (Jaramillo et al.,  2018).  
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From the results of this study, we conservatively estimate that, based on the 
volume of waste turned into the Vermont takeback programs in 2016 (Governor, 2017), 
combined with the participation rate from this survey, that approximately 8,400 pounds 
of pharmaceuticals may be wasted each year in Vermont. For example, in Vermont, 60% 
reported leftover, however only 16% participated and 2,500 pounds was received (Table 
4). Thus, the fate of the leftover medication associated with the remaining 44% of the 
population is unknown, however based on reported disposal behavior, the remaining 
waste is likely either stored (19%) or disposed (25%) (Table 4).   
However, as described, the waste turned into takeback programs is likely only a 
fraction of the total volume of pharmaceutical waste. Reviews on disposal behavior find 
a minority of consumers takeback medication, while the majority keep or dispose through 
other methods (Tong et al., 2011). Furthermore, the majority of surveyed population 
report leftover medication. 
This study appears to be the first study to evaluate disposal behavior on a state-
wide basis. Although the findings are not easily generalizable, the 60% of the population 
in this study reporting leftover medication is consistent with other studies (Zero Waste 
Washington, 2006; Ekedahl, 2006; Persson, 2009; Braund et al., 2009).   
Generally, leftover medication has two fates; either it is kept or disposed as a 
form of waste, based on the results of this study. If medication is kept, leftover 
medication may potentiate public health risks. A significant amount of research on 
patient use (and non-use) exists, particularly when non-use or over-use leads to adverse 
health effects (Horne, 2006). Both non-use as well as over-use indirectly relate to 
leftover medication; the first results in a portion of the prescription going unused, 
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becoming “leftover,” while the latter is associated with issues related to abuse, 
poisoning, overdose and diversion.  
If medication is disposed, disposal may potentiate various forms of 
environmental pollution. We found that 25% of Vermonters who participated in this 
study reported disposal behavior associated with high environmental impact (trash and 
flushing). What is known is that the volume of pharmaceutical waste appears to be 
substantial, and estimates suggest that pharmaceutical waste will continue to increase 
(Kantor, 2015). The volume of waste itself and the potential societal and environmental 
impacts of waste, combined with findings on disposal behavior justifies the need for 
takeback programs.  The magnitude of disposal as a source remains unknown, in 
relation to the other known source: pharmaceutical use and excretion, which is likely 
the greater source (Vatovec et al., 2016), however surveys on disposal behavior have 
provided vital information to support disposal as a potential source of environmental 
pollution. 
Environmental researchers concerned with waste and pollution have called for 
lower dose prescribing among healthcare providers, as well as greater collaboration 
with medical researchers, based on mutually-aligned interests (Daughton and Ruhoy, 
2014). While there may not necessarily be a mutual interest in the issue, there is 
certainly a mutually-aligned interest. “Drug disposal has interested medical 
professionals primarily because of insights it can yield on issues related to patient 
compliance and economic costs to the consumer. The driving force has rarely emanted 
from the potential for environmental benefits, although progress towards one aim is 
often relevant to the other – they are intimately tied together… Protecting the health, 
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safety, and pocketbook of the patient holds potential for protecting the environment – 
and vice versa” (Daughton, 2003b). Reducing wasted medication could further reduce 
the economic costs of medications (Fasola, 2014).  
Therefore, pharmaceutical waste may be impacting public health, the 
environment, and the economy. The impact on the economy is largely unknown, however 
medication that may become “leftover” represents wasted consumer spending (Morgan, 
2001). The financial costs of wasted medication are one aspect of the economic impacts 
of pharmaceutical waste. Additional costs are associated with the municipal costs of 
funding, establishing and managing takeback programs.  
An estimated cost of operating three takeback programs in Washington state for 
one year was $500,000 (Zero Waste Washington, 2012). This takeback program appears 
to be funded by a public-private partnership between local governments and local 
pharmaceutical companies (MED-Project, 2017). This partnership, however, appears to 
be an anomaly. All takeback programs are managed by governments as a public service, 
and most appear to be funded exclusively with public funding, but some are funded 
through public-private partnerships, with additional funding from philanthropies and 
nonprofits, not pharmaceutical companies. Washington state, and more importantly, the 
case of Alameda, California, are two exceptions, which represent the future of funding 
for the programs. Alameda county was the first municipality to successfully pass 
legislation requiring pharmaceutical manufacturers to fund takeback programs (Alameda 
County, 2017). The pharmaceutical industry filed an appeal, which eventually led to a 
judgment by the Supreme Court in favor of Alameda Country ruling that the 
pharmaceutical industry is liable for funding these programs (Mukherjee, 2016). Since 
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then, multiple states have successfully passed similar legislation to expand takeback 
programs in their states, despite heavy lobbying against these measures by the 
pharmaceutical industry (Massachusetts, 2017). In addition to funding the actual program 
itself, the industry is now required to fund the costs of disposal.  
The costs of managing the waste may include the financial costs of funding, 
expanding and maintaining takeback programs, the logistical costs associated with 
planning and coordination needed to establish the programs between multiple 
stakeholders (government, pharmacy, police, waste management), as well as the costs of 
public education campaigns, to increase participation in takeback programs. These costs 
may represent a significant impact on the economy.  
Takeback Programs as a Solution 
Takeback programs may address some of the public health and environmental 
issues surrounding leftover medication. Takeback programs are recommended not only 
to remove medication from the home, but also based primarily on the comparatively low 
environmental impact of this disposal method (EPA, 2017d). Pharmaceutical waste is 
disposed through hazardous waste incineration, which is said to degrade the chemicals, 
release the waste into the air, and therefore minimize release into, and thus impact on the 
aquatic environment (EPA, 2017c). The impact of the air pollution on surrounding 
communities was acknowledged by the WHO in their recommendation for incineration 
of pharmaceutical waste (WHO, 1995). Although the recommendation continues to be 
debated (Cook et al., 2012; Daughton, 2012), takeback programs are increasingly 
regarded as an effective solution to address the need for proper disposal (Glassmeyer et 
al., 2009).  
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 Takeback programs may be able to minimize the problems associated with 
pharmaceutical waste, however takeback programs do not prevent the waste itself.  If a 
consumer “takes-back” medication, this removes the medication from the home, which 
may prevent abuse or diversion, and this may mitigate disposal behavior that would 
otherwise contribute toward environmental pollution, however the programs cannot 
redress the financial costs of the waste on the consumer population. Furthermore, the 
programs themselves, or more accurately the waste itself, imposes an economic burden 
on society, and on the environment. Pharmaceutical takeback programs involve 
significant costs needed for operation, and incineration of the waste is associated with 
additional environmental impacts associated with air pollution. While takeback programs 
are certainly part of the solution, the greater solution lies in prevention of the waste itself.   
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CHAPTER 7: CONCLUSION 
 
This study evaluated purchasing, use and disposal behavior in order to 
recommend strategies to minimize environmental pollution. We found a large proportion 
of the surveyed population reported purchasing of medication, as well as leftover 
medication, and that a significant proportion reported disposal through the trash or 
through flushing, both known pathways leading to pollution in the environment. Given 
that leftover medication was common, this study sought to understand what happens to 
waste, or more generally, what consumers do with leftover medication. We found that 
disposal behavior varies based on the method of disposal, and that the impact of disposal 
behavior also varies. A large portion of the survey population reported participating in 
takeback programs, but our results indicate that participation is reported alongside other 
disposal behaviors associated with environmental pollution. Therefore, the findings of 
this study suggests that participation in takeback programs could be strengthened. One 
primary way to increase participation in takeback programs would be to incentivize 
clinicians and pharmacists to educate patients about proper disposal. Public campaigns 
in pharmacies could promote awareness of the program itself, along with the 
environmental impact of improper disposal. Future studies should consider focusing on 
the educational, informational and awareness factors that may influence disposal, as well 
as the logistic factors needed to incorporate disposal education into healthcare settings, 
namely clinics and pharmacies. The conclusion of this study is that disposal may be 
contributing towards environmental pollution downstream, which reinforces the need for 
greater research upstream, to minimize leftover medication, minimize disposal and thus, 
minimize pollution at its source. Future research should consider further study of 
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consumer purchasing, use and disposal behavior, to better understand leftover 
medication, not only to develop strategies to increase participation in takeback programs, 
but also to identify strategies to minimize leftover medication, and therefore to minimize 
many of the associated impacts on public health and the environment.   
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